Niraparib

What is Niraparib?

Niraparib is an oral medication classified as a poly (ADP-ribose) polymerase (PARP) inhibitor. Marketed under the brand name Zejula, it represents a significant advancement in targeted cancer therapy. Primarily used in the treatment of certain types of cancer, particularly ovarian cancer, it works by interfering with DNA repair mechanisms in cancer cells, leading to their death. This innovative approach offers a new lifeline for patients, especially those who have responded to platinum-based chemotherapy.

As a targeted therapy, Niraparib is distinct from traditional chemotherapy, focusing on specific molecular pathways involved in cancer growth and survival. Its development underscores a deeper understanding of cancer biology and the potential for precision medicine. It's often employed as a maintenance therapy, aiming to delay disease progression and extend the period of remission for eligible patients.

How Does it Work?

The core mechanism of action for Niraparib revolves around its inhibition of Poly (ADP-ribose) polymerase (PARP-1 and PARP-2) enzymes. PARP enzymes play a crucial role in the repair of single-strand DNA breaks through the base excision repair (BER) pathway. By inhibiting PARP, Niraparib prevents cancer cells from effectively repairing their DNA.

Furthermore, Niraparib also 'traps' PARP enzymes on DNA, forming PARP-DNA complexes that are highly toxic to cells. This leads to an accumulation of DNA damage, particularly double-strand breaks. Cancer cells with existing defects in homologous recombination repair (HRR), such as those with a BRCA mutation, are particularly vulnerable to this accumulation of DNA damage. This phenomenon is known as 'synthetic lethality,' where the combination of PARP inhibition and a pre-existing HRR defect leads to selective killing of cancer cells, while healthy cells with intact HRR pathways can still repair the damage.

Medical Uses

Niraparib is approved for specific indications, primarily in the management of ovarian, fallopian tube, and primary peritoneal cancers. Its key uses include:

• Maintenance Treatment: For adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. This use aims to extend the time before the cancer returns or progresses.
• Treatment of Advanced Cancer: For adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status. This includes patients with a positive BRCA mutation and/or genomic instability.

The efficacy of Niraparib is particularly pronounced in patients with platinum-sensitive disease, meaning their cancer has responded well to platinum-based chemotherapy. Clinical trials have demonstrated its ability to significantly improve progression-free survival (PFS) in these populations, thereby offering valuable additional time without disease progression.

Dosage

The recommended starting dose of Niraparib is typically 300 mg taken orally once daily. It can be taken with or without food. However, the dosage may be adjusted based on individual patient factors, including body weight and blood counts. For instance, patients weighing less than 58 kg may start with a lower dose of 200 mg once daily.

Close monitoring of blood counts, particularly platelets, neutrophils, and hemoglobin, is crucial during treatment. Dose reductions or temporary interruptions may be necessary if a patient experiences significant hematologic toxicities (e.g., severe thrombocytopenia, neutropenia, or anemia). It is imperative that patients strictly follow their healthcare provider's instructions regarding dosage and administration, and never adjust the dose without medical consultation.

Side Effects

Like all medications, Niraparib can cause side effects. Many are manageable, but some can be serious. Common side effects include:

• Nausea and vomiting
• Fatigue and asthenia (weakness)
• Anemia, thrombocytopenia (low platelet count), and neutropenia (low white blood cell count)
• Abdominal pain and constipation
• Headache
• Insomnia
• Hypertension (high blood pressure)

More serious, though less common, side effects can include Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML), which are severe blood disorders. Patients should undergo regular blood tests to monitor for these and other potential adverse effects. Hypertension is also a notable concern, and blood pressure should be monitored regularly. Patients should immediately report any unusual bruising, bleeding, fever, or persistent fatigue to their doctor.

Drug Interactions

While Niraparib is primarily metabolized by carboxylesterases and UGT1A1, and to a lesser extent by CYP3A4, it has a relatively low potential for significant drug interactions compared to some other cancer therapies. However, it's important to be aware of potential interactions:

• CYP3A4 Inhibitors/Inducers: While Niraparib is a substrate of CYP3A4, strong inhibitors or inducers of this enzyme are not expected to significantly alter its exposure. However, caution is always advised.
• Drugs Affecting Bone Marrow: Concomitant use with other myelosuppressive agents (drugs that suppress bone marrow function, like certain chemotherapies) may increase the risk of hematologic toxicities.

Patients should always inform their healthcare provider about all medications they are taking, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins, to identify and manage any potential drug interactions.

FAQ

Is Niraparib chemotherapy?

No, Niraparib is not traditional chemotherapy. It is a targeted therapy known as a PARP inhibitor. While chemotherapy broadly targets rapidly dividing cells, Niraparib specifically interferes with DNA repair mechanisms in cancer cells, particularly those with existing DNA repair defects.

How long do you take Niraparib?

As a maintenance therapy, Niraparib is typically taken long-term, often until disease progression or the development of unacceptable toxicity. The duration of treatment is determined by the patient's response and tolerance, under the guidance of their oncologist.

What is the success rate of Niraparib?

The 'success rate' of Niraparib is often measured by its ability to extend progression-free survival (PFS). Clinical trials have shown significant improvements in PFS, especially in patients with platinum-sensitive recurrent ovarian cancer, with benefits being most pronounced in those with BRCA mutations or HRD-positive status. Success varies widely based on individual patient characteristics and disease stage.

Can Niraparib cause hair loss?

Hair loss (alopecia) is a possible side effect of Niraparib, but it is generally less common and less severe than the hair loss associated with traditional cytotoxic chemotherapy. Not all patients experience it, and when it does occur, it's often mild.

Who is eligible for Niraparib?

Eligibility for Niraparib depends on specific criteria, including the type of cancer (ovarian, fallopian tube, or primary peritoneal), prior treatment history (e.g., response to platinum-based chemotherapy), and sometimes genetic testing results (e.g., BRCA mutation or HRD status). A healthcare professional will determine if a patient is an appropriate candidate.

Products containing Niraparib are available through trusted online pharmacies. You can browse Niraparib-based medications at ShipperVIP or Medicenter.

Summary

Niraparib is a crucial oral PARP inhibitor offering significant benefits in the management of ovarian, fallopian tube, and primary peritoneal cancers. Its mechanism of action, exploiting the concept of synthetic lethality, particularly in cells with a BRCA mutation or other homologous recombination deficiencies, marks it as a cornerstone of modern targeted cancer therapy. Primarily used as a maintenance therapy, it helps to delay disease progression and improve outcomes for eligible patients. While generally well-tolerated, it is essential for patients to be aware of potential side effects and to adhere strictly to medical guidance regarding dosage and monitoring. As research continues, Niraparib remains a vital tool in the ongoing fight against these challenging cancers.